ArticleJHEP reports : innovation in hepatology2026
The Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLD.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) is histologically staged using the 5-tiered NASH CRN system, which has limited resolution for advanced fibrosis stages that are strongly associated with liver-related outcomes. We developed and validated an expanded histological staging system designed to more accurately reflect the spectrum of MASLD fibrosis. Methods: Nine expert hepatopathologists from the Elucidating Pathways of Steatohepatitis (EPoS) Histopathology Group reviewed MASLD liver biopsies to define, by consensus, the fibrosis stages of a new histological scoring system. To assess validity, correlations with quantitative collagen proportionate area (CPA), enhanced liver fibrosis (ELF) score, and liver stiffness measurement (LSM) were evaluated. To assess inter-observer variability and intra-observer agreement, each pathologist independently reviewed 45 cases (glass slides) using the EPoS staging system. After three months, the same slides were digitized and re-evaluated by each pathologist, blinded to their previous assessments. Results: The EPoS staging system comprises seven stages (0-6), covering the full spectrum of MASLD fibrosis. Compared with the NASH CRN system, stages 1a, 1b, and 1c were combined into a single stage, while stages 3 and 4 were each subdivided into two additional stages. The EPoS system showed significant correlations with CPA, ELF score, and LSM values (all Conclusions: The EPoS fibrosis staging system is a robust expanded scoring method that accurately reflects histological CPA, LSM, and ELF values. EPoS staging may be useful for assessing fibrosis in MASLD natural history studies and therapeutic trials. Digital pathology provides results comparable to glass slides for reproducible fibrosis staging. Impact and implications: The traditional 5-tiered NASH CRN system for staging metabolic dysfunction-associated steatotic liver disease (MASLD)-related fibrosis has limited resolution for advanced stages, which are most strongly associated with liver-related outcomes. The newly developed and validated EPoS expanded 7-tiered staging system provides greater granularity for advanced fibrosis and more accurately reflects fibrosis progression in MASLD. The EPoS system is expected to improve the accuracy of fibrosis staging for patient selection in MASH (metabolic dysfunction-associated steatohepatitis) clinical trials and for assessing changes in fibrosis during both natural disease progression and therapeutic interventions, as well as in routine pathology practice. In addition, we demonstrate that digital pathology slides can be reliably used for reproducible fibrosis staging in MASLD, yielding results comparable to those obtained from glass slides, with direct practical implications for liver biopsy interpretation using scanned images.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.